OncXerna Therapeutics is proud to announce @JCO_ASCO publication featuring Phase 1b data of navicixizumab plus paclitaxel in ovarian cancer.
Read more here: https://t.co/IZjumGvo28, https://t.co/D4gYtVgHyR
#OvarianCancer#XernaTME#navi
Today, we are pleased to announce a licensing agreement with @ExactSciences. Together we will bring OncXerna’s Xernaᵀᴹ TME Panel to more patients. Read more here: https://t.co/reeWfRONkK